Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib in Chronic Spontaneous Urticaria
NCT07219615Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of ritlecitinib tosilate in chronic spontaneous urticaria (CSU), sponsored by Pfizer. Started Oct 2025; status: recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07219615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219615.